These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8724448)

  • 21. Scopolamine impairs memory recall in Octopus vulgaris.
    Fiorito G; Agnisola C; d'Addio M; Valanzano A; Calamandrei G
    Neurosci Lett; 1998 Sep; 253(2):87-90. PubMed ID: 9774156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans.
    Vitiello B; Martin A; Hill J; Mack C; Molchan S; Martinez R; Murphy DL; Sunderland T
    Neuropsychopharmacology; 1997 Jan; 16(1):15-24. PubMed ID: 8981385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed matching-to-sample performance by rats in a new avoidance-motivated maze: response to scopolamine and fimbria-fornix lesions.
    Bresnahan EL; Wiser PR; Muth NJ; Ingram DK
    Physiol Behav; 1992 Apr; 51(4):735-46. PubMed ID: 1594672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the central cholinergic projections in cognition: implications of the effects of scopolamine on discrimination learning by monkeys.
    Harder JA; Baker HF; Ridley RM
    Brain Res Bull; 1998; 45(3):319-26. PubMed ID: 9510426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties.
    Kennedy DO; Wake G; Savelev S; Tildesley NT; Perry EK; Wesnes KA; Scholey AB
    Neuropsychopharmacology; 2003 Oct; 28(10):1871-81. PubMed ID: 12888775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRH attenuates scopolamine-induced memory impairment in humans.
    Molchan SE; Mellow AM; Lawlor BA; Weingartner HJ; Cohen RM; Cohen MR; Sunderland T
    Psychopharmacology (Berl); 1990; 100(1):84-9. PubMed ID: 2104988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholinergic-dependent cognitive deficits in Parkinson's disease.
    Dubois B; Danzé F; Pillon B; Cusimano G; Lhermitte F; Agid Y
    Ann Neurol; 1987 Jul; 22(1):26-30. PubMed ID: 3631918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys.
    Callahan MJ; Kinsora JJ; Harbaugh RE; Reeder TM; Davis RE
    Neurobiol Aging; 1993; 14(2):147-51. PubMed ID: 8487917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probing peripheral and central cholinergic system responses.
    Naranjo CA; Fourie J; Herrmann N; Lanctôt KL; Birt C; Yau KK
    J Psychiatry Neurosci; 2000 Sep; 25(4):325-36. PubMed ID: 11022397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human information-processing: some effects of methylphenidate, age, and scopolamine.
    Callaway E
    Biol Psychiatry; 1984 May; 19(5):649-62. PubMed ID: 6733179
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations.
    Sunderland T; Tariot PN; Newhouse PA
    Brain Res; 1988 Dec; 472(4):371-89. PubMed ID: 3066441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of scopolamine on working memory in healthy young volunteers.
    Rusted JM; Warburton DM
    Psychopharmacology (Berl); 1988; 96(2):145-52. PubMed ID: 3148139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scopolamine impairs learning performance of rats in a 14-unit T-maze.
    Spangler EL; Rigby P; Ingram DK
    Pharmacol Biochem Behav; 1986 Sep; 25(3):673-9. PubMed ID: 3022309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance.
    Parrott AC
    Psychopharmacology (Berl); 1986; 89(3):347-54. PubMed ID: 3088662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task.
    Wesnes K; Warburton DM
    Neuropsychobiology; 1983; 9(2-3):154-7. PubMed ID: 6621852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scopolamine impairs acquisition and facilitates consolidation of fear conditioning: differential effects for tone vs context conditioning.
    Young SL; Bohenek DL; Fanselow MS
    Neurobiol Learn Mem; 1995 Mar; 63(2):174-80. PubMed ID: 7663891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans.
    Little JT; Broocks A; Martin A; Hill JL; Tune LE; Mack C; Cantillon M; Molchan S; Murphy DL; Sunderland T
    Psychopharmacology (Berl); 1995 Aug; 120(3):280-8. PubMed ID: 8524975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic modelling of Alzheimer's disease.
    Sunderland T; Tariot PN; Weingartner H; Murphy DL; Newhouse PA; Mueller EA; Cohen RM
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):599-610. PubMed ID: 3541054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests.
    Kennedy RS; Odenheimer RC; Baltzley DR; Dunlap WP; Wood CD
    Aviat Space Environ Med; 1990 Jul; 61(7):615-21. PubMed ID: 2386447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.